| |
Simple analysis
|
Multiple analysis
|
|---|
| |
HR
|
95% CI
|
p-value
|
HR
|
95% CI
|
p-value
|
|---|
|
Sex
| | | | | | |
|
Female
|
1
| | | | | |
|
Male
|
1.16
|
0.81-1.67
|
0.41
| | | |
|
Age, median 74
| | | | | | |
|
<74
|
1
| | | | | |
|
≥74
|
1.14
|
0.80-1.64
|
0.47
| | | |
|
T category
| | | | | | |
|
T3
|
1
| | |
1
| | |
|
T4
|
3.65
|
2.46-5.43
|
<0.0001
|
2.69
|
1.74-4.16
|
<0.0001
|
|
Malignancy grade
| | | | | | |
|
Medium + Low
|
1
| | |
1
| | |
|
High*
|
1.49
|
0.98-2.27
|
0.06
|
1.42
|
0.92-2.18
|
0.11
|
|
Localisation
| | | | | | |
|
Right
|
1
| | | | | |
|
Left
|
1.12
|
0.78-1.60
|
0.54
| | | |
|
Perforation
| | | | | | |
|
No
|
1
| | |
1
| | |
|
Yes
|
3.66
|
2.34-5.73
|
<0.0001
|
2.57
|
1.54-4.30
|
0.0003
|
|
Fixation
| | | | | | |
|
No
|
1
| | |
1
| | |
|
Yes
|
2.49
|
1.69-3.67
|
<0.0001
|
1.32
|
0.83-2.10
|
0.23
|
|
Lymph nodes
| | | | | | |
|
≥12
|
1
| | | | | |
|
<12
|
0.85
|
0.59-1.22
|
0.37
| | | |
|
Neuronal invasion
| | | | | | |
|
No
|
1
| | |
1
| | |
|
Yes
|
2.05
|
1.24-3.38
|
0.005
|
1.46
|
0.84-2.55
|
0.18
|
|
Vascular invasion
| | | | | | |
|
No
|
1
| | |
1
| | |
|
Yes
|
2.00
|
1.27-3.16
|
0.003
|
1.61
|
1.00-2.61
|
0.05
|
|
MSI status
| | | | | | |
|
MSI
|
1
| | | | | |
|
MSS
|
1.39
|
0.90-2.15
|
0.14
| | | |
|
miRNA-126
| | | | | | |
|
<median
|
1
| | |
1
| | |
|
>median
|
0.72
|
0.50-1.04
|
0.08
|
0.96
|
0.66-1.40
|
0.83
|
|
MVD
| | | | | | |
|
<median
|
1
| | | | | |
|
>median
|
0.88
|
0.61-1.26
|
0.49
| | | |
- HR: hazard ratio; CI: confidence interval; MSI: microsatellite instability; MSS: microsatelite stable; miRNA-126: microRNA-126; MVD: microvessel density.
- *Including mucinous and sigillocellular adenocarcinomas.
- Significant p-values are highlighted in bold.
